Preliminary data from the INSIGHT 2 study suggested that the combination of tepotinib and osimertinib has activity in patients with EGFR-mutated advanced NSCLC with MET amplification who progressed on first-line osimertinib. This evidence concerns the gene MET and non-small cell lung carcinoma.